MELD-ATG Trial
Recruitment closed
October 2023
This clinical study with anti-thymocyte globulin (ATG), supplied by Sanofi, aims to examine the activity and dose schedule of ATG in children and young adults who have recently been diagnosed with T1D in order to reduce disease progression at the earliest possible time.
Open to recruitment:
- Addenbrooke’s Hospital, Cambridge (At capacity)
- The Royal London Hospital (At capacity)
-
Oxford Children’s Hospital (At capacity)
Conditions for participation
- Are you aged between 5 and 25?
- Has type 1 diabetes been diagnosed in you in the past 6 weeks?
Visits during follow-up
If you are interested in taking part, please click the “Get Involved” button below:
